一个腺协同的正反循环延长了药理心脏保护的持续时间
Gerald Wölkart1, Simon Gissing1, Heike Stessel1
1Department of Pharmacology and Toxicology, University of Graz, Graz, Austria.
British journal of pharmacology
|September 11, 2024
概括
一个积极的反循环涉及腺素受体诱导的腺素激酶 (ADK) 降解延长心脏保护的持续时间. 这种在小鼠中证明的机制为持续的腺能心脏保护提供了针对心脏损伤的潜力.
科学领域:
- 心血管生理学心血管生理学
- 分子心脏病学分子心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 腺素受体的激活提供了延迟的心脏保护,防止缺血-再输液 (IR) 损伤.
- 腺诱导心脏保护的延长时间 (24-72小时) 的机制尚不清楚.
- 假设的积极反循环涉及腺酶 (ADK) 降解和减少腺代谢.
研究的目的:
- 调查腺激酶 (ADK) 降解在延长腺介导心脏保护中的作用.
- 阐明维持心脏保护的积极反机制.
- 探索持续的腺协同信号的治疗潜力.
主要方法:
- 用ADK抑制剂 (ABT-702) 诱导内源性腺信号传递的小鼠.
- 在不同时间点对心脏ADK蛋白和mRNA水平的分析.
- 药理上抑制腺受体或蛋白酶体以评估晚期影响.
- 使用兰根多夫技术和IR耐受性测试对心脏保护的评估.
- 在心脏特异性ADK淘汰赛 (cADK+/-) 小鼠中的评估.
主要成果:
- ABT-702治疗降低了心脏ADK蛋白,并从24-72小时内提供心脏保护.
- 氨酸受体或蛋白质酶抑制逆转了ADK缺陷,并取消了心脏保护.
- 特定于心脏的ADK异合性绝杀心脏证明了持续的心脏保护.
- 各种预调剂也降低了心脏ADK蛋白表达.
结论:
- 一个积极的反循环,由腺素受体介导的ADK降解启动,维持心脏保护.
- 这种机制延长了ABT-702和潜在的其他预条件剂的保护作用.
- 持续的腺协同心脏保护显示出治疗前景,正如cADK+/-小鼠所证明的那样.
更多相关视频
08:49Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
678
06:40Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
Published on: May 22, 2018
10.7K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
01:26Heart Failure Drugs: Inotropic Agents
543
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
543
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
01:20Desensitization and Tachyphylaxis
1.6K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.6K
01:22Heart Failure Drugs: β-Blockers
321
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
321
01:16Antianginal Drugs: Nitrates and β-Blockers
543
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
543